Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

Merck KGaA (EMD Serono)

Status: Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Study type: Observational

Funder types: Industry

Identifiers

NCT04997148

MS700568_0150

Details and patient eligibility

About

The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.

Enrollment: 116 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Physician diagnosis of HDA-RRMS as defined by clinical or radiological features
• Treatment initiation with cladribine tablet monotherapy on or after 22 August 2017 and at least 3 years before enrolment
• Completion of Year 1 treatment of cladribine tablets (Week 1 and Week 2 treatment, per recommended dose in Year 1: 1.75 milligrams per kilogram [mg/kg] body weight, cumulatively)

Exclusion criteria

• Received cladribine tablet treatment within an interventional clinical trial during the study period
• Received treatment with any investigational therapy for RRMS in the 6 months prior to cladribine tablet treatment initiation

Trial design

116 participants in 1 patient group

Cladribine

Description:

No intervention was administered as a part of this study. Participants with Highly-active Disease Relapsing-remitting Multiple Sclerosis (HDA-RRMS), who completed at least Year 1 of treatment with cladribine tablets in routine clinical practice were enrolled into this study and assessed up to maximum 5 years after cladribine tablets initiation.